KPTI Phase 3 readout: a negative outcome, -5.8%

On October 28, 2020, Selinexor — Karyopharm Therapeutics Inc. (Multiple Myeloma, Refractory) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -5.8% in the window around the event. It had already run +5.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.